New study to reveal hidden weaknesses in vaccines for Immune-Compromised patients
NCT ID NCT06612515
First seen May 13, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study will follow 1,000 immunocompromised patients, including those with blood cancers, to see how their immune systems respond to vaccines against respiratory viruses like flu and COVID-19. Researchers will measure both antibody levels and T cell responses, which may offer better protection. The goal is to understand why vaccines often work less well in these patients and how to improve protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Cologne
RECRUITINGCologne, North Rhine-Westphalia, 50937, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.